Modulation of monocytic Gal-9/PD-L1-expression or blocking the interaction between these ICMs and their cognate receptors with immune checkpoint inhibitors may thus represent a potential approach for reinvigoration of immune response in chronically HBV-infected patients, thereby facilitating viral clearance and cure of HBV-induced liver diseases. Here, LGALS9 is linked to liver disorder.